QUICK SPARK: Moderna Stock Drops 25%, Eyes Worst Day in Company's History
Key takeaways
- Moderna’s record rally was quickly erased by a 25.69% slide, reflecting the high stakes of its first Phase 3 mRNA cancer therapy and the weight of its short‑interest profile.
- MRNA fell 25.69% on Thursday
- MRNA rallied 176.97% on Wednesday
- Short interest ≈12.5% of float
What happened
Moderna (MRNA) stock fell 25.69% on Thursday after a record 176.97% rally the previous day, driven by positive late‑stage Phase 3 results for its intismeran autogene cancer vaccine.
Why it matters
The drop marks the worst single‑day decline in the company’s history, highlighting the volatility of biotech stocks even after breakthrough trial results and underscoring the impact of short interest (≈12.5% of float).
Short-term and longer-term
Short-term. Short sellers likely rushed in as the rally stalled, pushing the price sharply lower.
Longer-term. The episode highlights the high risk/reward nature of Moderna’s oncology bets.